Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
41
pubmed:dateCreated
1999-11-9
pubmed:abstractText
Sustained activation of most G protein-coupled receptors causes a time-dependent reduction of receptor density in intact cells. This phenomenon, known as down-regulation, is believed to depend on a ligand-promoted change of receptor sorting from the default endosome-plasma membrane recycling pathway to the endosome-lysosome degradation pathway. This model is based on previous studies of epidermal growth factor (EGF) receptor degradation and implies that receptors need to be endocytosed to be down-regulated. In stable clones of L cells expressing beta(2)-adrenergic receptors (beta(2)ARs), sustained agonist treatment caused a time-dependant decrease in both beta(2)AR binding sites and immuno-detectable receptor. Blocking beta(2)AR endocytosis with chemical treatments or by expressing a dominant negative mutant of dynamin could not prevent this phenomenon. Specific blockers of the two main intracellular degradation pathways, lysosomal and proteasome-associated, were ineffective in preventing beta(2)AR down-regulation. Further evidence for an endocytosis-independent pathway of beta(2)AR down-regulation was provided by studies in A431 cells, a cell line expressing both endogenous beta(2)AR and EGF receptors. In these cells, inhibition of endocytosis and inactivation of the lysosomal degradation pathway did not block beta(2)AR down-regulation, whereas EGF degradation was inhibited. These data indicate that, contrary to what is currently postulated, receptor endocytosis is not a necessary prerequisite for beta(2)AR down-regulation and that the inactivation of beta(2)ARs, leading to a reduction in binding sites, may occur at the plasma membrane.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/Adrenergic beta-2 Receptor Agonists, http://linkedlifedata.com/resource/pubmed/chemical/Cysteine Endopeptidases, http://linkedlifedata.com/resource/pubmed/chemical/Dynamins, http://linkedlifedata.com/resource/pubmed/chemical/Epidermal Growth Factor, http://linkedlifedata.com/resource/pubmed/chemical/GTP Phosphohydrolases, http://linkedlifedata.com/resource/pubmed/chemical/Isoproterenol, http://linkedlifedata.com/resource/pubmed/chemical/Multienzyme Complexes, http://linkedlifedata.com/resource/pubmed/chemical/Proteasome Endopeptidase Complex, http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Adrenergic, beta-2, http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Fusion Proteins, http://linkedlifedata.com/resource/pubmed/chemical/Serine Proteinase Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Ubiquitins
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0021-9258
pubmed:author
pubmed:issnType
Print
pubmed:day
8
pubmed:volume
274
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
28900-8
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed-meshheading:10506134-Adrenergic beta-2 Receptor Agonists, pubmed-meshheading:10506134-Animals, pubmed-meshheading:10506134-Binding Sites, pubmed-meshheading:10506134-Cell Line, pubmed-meshheading:10506134-Cell Membrane, pubmed-meshheading:10506134-Cysteine Endopeptidases, pubmed-meshheading:10506134-Down-Regulation, pubmed-meshheading:10506134-Dynamins, pubmed-meshheading:10506134-Endocytosis, pubmed-meshheading:10506134-Epidermal Growth Factor, pubmed-meshheading:10506134-GTP Phosphohydrolases, pubmed-meshheading:10506134-Gene Expression, pubmed-meshheading:10506134-Humans, pubmed-meshheading:10506134-Isoproterenol, pubmed-meshheading:10506134-L Cells (Cell Line), pubmed-meshheading:10506134-Lysosomes, pubmed-meshheading:10506134-Mice, pubmed-meshheading:10506134-Microscopy, Fluorescence, pubmed-meshheading:10506134-Multienzyme Complexes, pubmed-meshheading:10506134-Proteasome Endopeptidase Complex, pubmed-meshheading:10506134-Receptors, Adrenergic, beta-2, pubmed-meshheading:10506134-Recombinant Fusion Proteins, pubmed-meshheading:10506134-Serine Proteinase Inhibitors, pubmed-meshheading:10506134-Ubiquitins
pubmed:year
1999
pubmed:articleTitle
Beta(2)-adrenergic receptor down-regulation. Evidence for a pathway that does not require endocytosis.
pubmed:affiliation
Immuno-Pharmacologie Moléculaire, UPR 415 of CNRS, 75014 Paris, France.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, Non-P.H.S.